* BIOCRYST PHARMACEUTICALS - IND FOR NONCLINICAL DEVELOPMENT OF BCX9250,BCX9499 INITIATED WITH GOAL OF PROGRESSING TO PHASE 1 CLINICAL TRIALS IN H1 2019 Source text for Eikon: Further company coverage: